<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01442649</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE 18 / ACCORD 22/0906</org_study_id>
    <nct_id>NCT01442649</nct_id>
  </id_info>
  <brief_title>Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab</brief_title>
  <official_title>Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to evaluate progression-free survival (PFS) at 4 months.

      The secondary objectives are to evaluate the objective response rate (OR) (= complete
      responses (CR) and partial responses (PR)) according to the RECIST v1.1 criteria, the
      progression-free survival (PFS), the overall survival (OS), the overall survival from the
      date of the first-line chemotherapy used on the metastatic disease, the treatment tolerance
      (NCI CTC AE V4 criteria, except for peripheral neurological toxicity (Lévi Scale)), the
      quality of life according to the EORTC QLQ-C30 criteria.

      The objectives of the biological study are to evaluate potentially predictive anti-EGFR and
      anti-VEGF response factors and CEC rates as predictive biomarkers for the efficacy of
      bevacizumab associated with chemotherapy in mCRC treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) at 4 months</measure>
    <time_frame>4 months</time_frame>
    <description>Progression-free survival is defined as the time from randomization to progression (RECIST v1.1 criteria) or death. Patients alive without progression will be censored at the last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (OR)</measure>
    <time_frame>12 months</time_frame>
    <description>The objective response rate is defined as the occurence of a complete response [CR] or a partial responses [PR] according to RECIST V1.1 between date of randomization and date of end of treatment. It will be evaluated by the investigator with RECIST v1.1 criteria every 6 weeks up to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>4 months</time_frame>
    <description>Progression-free survival is defined as the time from randomization to progression (RECIST v1.1 criteria) or death. Patients alive without progression will be censored at the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>until death or progression (24 months)</time_frame>
    <description>Overall survival is defined as the time from randomization to death any cause or last follow-up (censored data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival from the date of the first-line chemotherapy used on the metastatic disease</measure>
    <time_frame>until death or progression (24 months)</time_frame>
    <description>Overall survival from the date of the first-line chemotherapy used on the metastatic disease is defined as the time from the first day of the first-line chemotherapy used on the metastatic disease to death any cause or last follow-up news (censored data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment tolerance</measure>
    <time_frame>Every 2 weeks, during the treatment.</time_frame>
    <description>Tolerance of the treatment will be based on toxicities of evaluated products by clinical and biological measurements (NCIC/CTC (CTCAE V4) criteria, except for peripheral neuropathy toxicity (Lévi scale)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>every 6 weeks</time_frame>
    <description>Quality of life will be evaluated with the EORTC QLQ - C30.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A : bevacizumab + fluoropyrimidine-based chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 2 weeks :
- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.
OR
- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.
AND
Bevacizumab 5 mg/kg IV every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : cetuximab + fluoropyrimidine-based chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 2 weeks :
- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.
OR
- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.
AND
Cetuximab : 500 mg/m² IV every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A : bevacizumab + fluoropyrimidine-based chemotherapy</arm_group_label>
    <arm_group_label>Arm B : cetuximab + fluoropyrimidine-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A : bevacizumab + fluoropyrimidine-based chemotherapy</arm_group_label>
    <arm_group_label>Arm B : cetuximab + fluoropyrimidine-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluoro-uracil</intervention_name>
    <description>400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A : bevacizumab + fluoropyrimidine-based chemotherapy</arm_group_label>
    <arm_group_label>Arm B : cetuximab + fluoropyrimidine-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A : bevacizumab + fluoropyrimidine-based chemotherapy</arm_group_label>
    <arm_group_label>Arm B : cetuximab + fluoropyrimidine-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A : bevacizumab + fluoropyrimidine-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>500mg/m² on D1 every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm B : cetuximab + fluoropyrimidine-based chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven adenocarcinoma of the colon expressing
             non-mutated (wild-type) KRAS.

          -  Progressive metastatic disease after first-line treatment with chemotherapy alone:
             based on 5-FU (iv or per os) with irinotecan or oxaliplatin associated to bevacizumab.

          -  Prior adjuvant chemotherapy (of the primary tumor) with fluoropyrimidine and
             oxaliplatin is allowed if the time interval between the end of this chemotherapy and
             the beginning of the first-line metastatic treatment is ≥ 6 months.

          -  Measurable disease (at least one measurable metastatic lesion) according to the RECIST
             V1.1 criteria (the lesion should not be located in a previous field of radiation).

          -  Previous radiotherapy is authorized if discontinued ≥ 15 days prior to randomization
             and if the measurable metastatic lesions are outside the radiation area.

          -  Sites of disease evaluated within 28 days prior to randomization with
             thoracic-abdominal-pelvic CT scan (or abdominal-pelvic MRI plus Chest Xray)

          -  Age ≥18 years

          -  Patient with ECOG 0 or 1

          -  Life Expectancy ≥ 3 months

          -  Hematologic function (polynuclear neutrophiles ≥ 1.5.109/L ; platelets ≥ 100.109/L ;
             hemoglobin ≥ 9 g/dL

          -  Hepatic transaminases ≤ 2.5 times upper limit of normal (ULN) (≤ 5 ULN in case of
             hepatic metastases), alkaline phosphatases ≤ 2.5 ULN (≤ 5 ULN in case of hepatic
             metastases), total bilirubinemia ≤ 1.5 ULN

          -  Renal function (creatinemia ≤1.5 ULN; creatine clearance ≥ 50 mL/mn (Cockcroft and
             Gault) ; urine test strip &lt; 2+. If proteinuria is ≥ +2 at inclusion, the serum urea
             test must be redone and show proteinuria ≤ 1 g/L within 24 h)

          -  Completion of the EORTC QLQ-C30 quality of life form

          -  Negative pregnancy test for women of child-bearing age

          -  Information given to the patient and signed informed consent

          -  Public Health insurance coverage

        Exclusion Criteria:

          -  Known meningeal or brain metastases

          -  Pre-treatment with anti-EGFR

          -  Specific contraindication or known hypersensitivity to one treatment product

          -  Patient with known allergy or hypersensitivity to monoclonal antibodies (bevacizumab,
             cetuximab

          -  Clinically significant affection of the coronaries or myocardial infarction within 6
             months prior to inclusion.

          -  Peripheral neuropathy of grade &gt; 1 (CTCAE scale version 4.0).

          -  Known depletion of the dihydropyrimidine dehydrogenase (DPD).

          -  Acute intestinal obstruction or sub-obstruction, history of inflammatory intestinal
             disease or extended resection of the small intestine. Presence of a colic prosthesis.

          -  Uncontrolled Arterial hypertension (systolic pressure &gt; 150 mmHg and/or diastolic
             pressure &gt; 100 mmHg with and without antihypertensive medication. Patients with high
             hypertension are eligible if antihypertensive medication lowers their arterial
             pressure to the level of acceptability specified by the inclusion criteria.

          -  History of hypertensive crisis or hypertensive encephalopathy

          -  Other concomitant malignancy or history cancer (except carcinoma in situ of the
             cervix, or non melanoma skin cancer, with curative intent treatment, when considered
             in complete remission for at least 5 years before randomization.

          -  Any treatment including an experimental drug, or participation in another clinical
             trial within 28 days preceding inclusion.

          -  Persons deprived of liberty or under guardianship.

          -  Psychological, familial, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaafar BENNOUNA, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre René Gauducheau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe BORG, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Jean Minjoz-BESANCON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian BOREL, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Paul Strauss-STRASBOURG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Pierre DELORD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud-TOULOUSE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe BORG, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier du Mittan-MONTBELIARD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-François SEITZ, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Timone-MARSEILLE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry CONROY, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Alexis Vautrin-VANDOEUVRE LES NANCY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger FAROUX, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD Vendée-LA ROCHE SUR YON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric FRANCOIS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne-NICE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alice GAGNAIRE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Bocage-DIJON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine ADENIS, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret-LILLE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cédric LECAILLE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polyclinique Bordeaux Nord Aquitaine-BORDEAUX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaël DEPLANQUE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe hospitalier St Joseph-PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal ARTRU, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Privé Jean Mermoz-LYON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oana COJOCARASU, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier du Mans-LE MANS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent MIGLIANICO, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHP Saint Grégoire-SAINT GREGOIRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier BOUCHE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Robert Debré - CHU Reims</affiliation>
  </overall_official>
  <overall_official>
    <last_name>You-Heng LAM, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Cholet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David TOUGERON, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Poitiers-POITIERS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara DAUVOIS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR d'Orléans - Hôpital la Source</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe HOUYAU, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Claude Bernard-ALBI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre rené Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Second-line treatment</keyword>
  <keyword>Progressive disease after first-line treatment with bevacizumab</keyword>
  <keyword>Non-mutated (wild-type) KRAS.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

